Back to Peptides
Peptides

TesamorelinEvidence & Dosage

Approved for HIV-associated lipodystrophy — visceral fat reduction.

Evidence at a glance

Total studies
82
With abstract
49
Meta / Systematic / RCT
2
Highly cited
33
Publication years
1993–2026

Tesamorelin in the context of Peptides

This topic is part of our "Peptides" world. There you'll find methodology, evidence and the highest-impact levers — plus the order in which they sensibly build on each other.

Go to Peptides

Top studies on Tesamorelin

Ranked by influential-citation count and publication year.

  1. Growth Hormone and IGF-1 Actions in the Brain and Neuropsychiatric Diseases

    Physiology202680 influential citations

    Growth hormone (GH) is secreted by the anterior pituitary gland under the control of hypothalamic neuroendocrine neurons that express somatostatin or growth hormone-releasing hormone (GHRH). Ghrelin, originating primarily in the stomach,…

  2. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection.

    The Journal of clinical endocrinology and metabolism199379 influential citations

    Body wasting, characterized by disproportionate loss of body cell mass, is a feature of many chronic diseases, including infection with the human immunodeficiency virus (HIV). Therapies that merely increase energy intake do not…

  3. Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.

    The Journal of clinical endocrinology and metabolism2021n=61B73 influential citations

    Growth hormone (GH) and IGF-1 help regulate hepatic glucose and lipid metabolism, and reductions in these hormones may contribute to development of nonalcoholic fatty liver disease (NAFLD). To assess relationships between hepatic…

  4. Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease.

    Therapeutics and clinical risk management202349 influential citations

    Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease without any approved treatment to-date despite intensive research efforts by researchers and pharmaceutical industry. Fibroblast growth factor (FGF)-21 has been gaining…

  5. Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin.

    Frontiers in endocrinology202444 influential citations

    Growth hormone (GH) is the key regulator of insulin-like growth factor I (IGF-I) generation in healthy states. However, portal insulin delivery is also an essential co-player in the regulation of the GH/IGF-I axis by affecting and…

  6. Growth hormone and aging: a clinical review.

    Frontiers in aging2025n=152D32 influential citations

    Aging is a complex biological process characterized by functional decline, reduced quality of life, and increased vulnerability to diseases such as type 2 diabetes, cardiovascular conditions, neurodegeneration, and cancer. Advances in…

  7. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

    The lancet. HIV2019n=61B30 influential citations

    Non-alcoholic fatty liver disease (NAFLD) is a substantial cause of comorbidity in people with HIV and there are no proven pharmacological treatments for the disease in this population. We assessed the effects of tesamorelin on liver fat…

  8. Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease.

    Clinical endocrinology2021n=10326 influential citations

    Background Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in young adults with obesity. Obesity is associated with relative growth hormone (GH) deficiency, and data from animal studies and from humans with pituitary GH…

  9. GHRH in diabetes and metabolism.

    Reviews in endocrine & metabolic disorders2025D26 influential citations

    Despite over a century of insulin therapy and recent advances in glucose monitoring, diabetes and its complications remain a significant burden. Current medications are not durable, with symptoms often returning after treatment ends, and…

  10. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling.

    Reviews in endocrine & metabolic disorders2025D26 influential citations

    The hypothalamic polypeptide growth hormone-releasing hormone (GHRH) stimulates the secretion of growth hormone (GH) from the pituitary through binding and activation of the pituitary type of GHRH receptor (GHRH-R), which belongs to the…

More topics in Peptides

Peptides Overview

Peptides, BPC-157, TB-500, safety and the state of the evidence.

Administration Routes

Subcutaneous, intramuscular, nasal, oral, topical — bioavailability and safety.

Autoimmunity Risk

Immune modulation can both promote tolerance and tip into dysregulation.

BPC-157

Peptide for tissue regeneration, healing, and athletic recovery.

Cerebrolysin

A pig-brain peptide mix, stroke studies, not approved in Germany.

CJC-1295

GHRH analog, half‑life variants and pulse patterns.

Dihexa

Angiotensin derivative, cognitive/neuroplasticity signals in animal models.

GHK-Cu

Copper peptide for skin health, anti-aging, and wound healing.

GHRP-2

GH releaser, older generation, appetite stimulation as a side effect.

GHRP-6

GH releaser with a strong appetite component.

GLP-1 Rebound

Weight regain after stopping without lifestyle anchors.

GLP-1 Side Effects

Nausea, gastric emptying, muscle loss, pancreatitis risk.

Hexarelin

GH releaser, fast tolerance build-up, cardiac signals.

IGF-1 LR3

Modified IGF-1 with a long half-life — hypertrophy, the cancer-risk debate.

Immune Modulation

Automatisch via Trend Scout entdeckt. Supplements targeting inflammation and immune resilience remain a central research area.. PubMed: 11956 Ergebnisse.

Injection Safety

Sterile technique, bacteriostatic water, skin disinfection — a medical topic.

Ipamorelin

Selective GH releaser, cortisol‑sparing, and stack combinations.

KPV

An alpha-MSH fragment — anti-inflammatory, gut, skin, early research.

Liraglutide

First-generation GLP-1 for diabetes/obesity — daily, smaller effect size.

LL-37

Antimicrobial peptide, wound healing, immune modulation, early research.

Related topics from other worlds